Ownership and insider activity for Rocket Pharmaceuticals, Inc. (RCKT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs.
Price
| Price | $3.48 |
| Market Cap | $380M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-11 | Wilson Martin | S-Sale | 75,364 | $256K |
| 2026-08-18 | Wilson Martin | S-Sale | 631 | $2K |
| 2026-08-18 | Shah Gaurav | S-Sale | 2,293 | $8K |
| 2026-08-13 | Shah Gaurav | S-Sale | 2,837 | $10K |
| 2026-08-13 | Wilson Martin | S-Sale | 3,493 | $12K |
| 2026-08-11 | Stevens Christopher James | S-Sale | 36,658 | $128K |
| 2026-08-11 | Chaudhuri Sarbani | S-Sale | 4,701 | $16K |
| 2026-08-03 | Stevens Christopher James | A-Award | 73,313 | |
| 2026-08-03 | Stevens Christopher James | A-Award | 101,428 | $346K |
| 2026-08-03 | SOUTHWELL DAVID P | J-Other | 150,000 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.8M | $78.7M | $111.4M | $185.4M | $297.1M | $232.7M | $140.5M | $55.9M | $163.6M | $77.6M |
| Short-term Investments | $96.7M | $21.3M | $94.4M | $118.7M | $185.6M | $156.0M | $215.9M | $317.3M | $208.7M | $111.4M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $128.3M | $101.0M | $209.1M | $307.8M | $487.3M | $392.1M | $364.1M | $378.2M | $378.2M | $192.7M |
| Property, Plant & Equipment | $1.1M | $563000 | $2.0M | $31.3M | $70.6M | $72.3M | $77.6M | $87.6M | $83.3M | $71.6M |
| Goodwill | 0 | 0 | $30.8M | $30.8M | $30.8M | $30.8M | $39.2M | $39.2M | $39.2M | $39.2M |
| Intangible Assets | 0 | 0 | 0 | $226000 | 0 | 0 | $25.7M | $25.1M | $25.1M | $25.1M |
| Total Assets | $129.6M | $101.8M | $251.3M | $372.1M | $590.8M | $497.0M | $551.8M | $566.3M | $527.7M | $330.4M |
| Accounts Payable | $1.6M | $451000 | 0 | 0 | 0 | 0 | 0 | 0 | $1.6M | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | $4.9M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $7.2M | $4.1M | $15.4M | $18.3M | $32.6M | $22.2M | $39.2M | $48.5M | $40.7M | $30.2M |
| Long-term Debt | $49.0M | $49.5M | $41.4M | $45.0M | $35.1M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $56.5M | $54.0M | $57.3M | $64.8M | $87.3M | $42.3M | $62.1M | $73.8M | $64.5M | $53.2M |
| Retained Earnings | -$238.9M | -$268.4M | -$105.9M | -$183.1M | -$322.8M | -$491.9M | -$713.8M | -$959.4M | -$1.22B | -$1.44B |
| Total Equity | $73.2M | $47.8M | $194.0M | $307.3M | $503.5M | $454.7M | $489.7M | $492.6M | $463.2M | $277.2M |
| Total Debt | $49.0M | $49.5M | $41.4M | $47.4M | $61.7M | $22.6M | $22.9M | $25.0M | $25.5M | $24.9M |
| Net Debt | -$77.5M | -$50.5M | -$164.3M | -$256.7M | -$421.0M | -$366.1M | -$333.5M | -$348.1M | -$346.8M | -$164.1M |
| Working Capital | $121.1M | $97.0M | $193.7M | $289.4M | $454.7M | $369.9M | $324.9M | $329.7M | $337.5M | $162.5M |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 9.24 |
Profitability
| Return on Equity | -5.76% |
| Return on Invested Capital | -48.55% |
| Return on Assets | -4.08% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANNX · AURA · AUTL · DBVT · DSGN · GALT · IMAB
Explore sector: Healthcare · Biotechnology
More sections of RCKT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks